FDA Approved 'Sham' Label For Cancer Drug, DC Circ. Told
Spectrum Pharmaceuticals Inc. pushed for a DC Circuit panel Thursday to toss the Food and Drug Administration's approval of a generic version of its cancer treatment Fusilev, calling the drug's label...To view the full article, register now.
Already a subscriber? Click here to view full article